SCHEMBL5996242

SCHEMBL5996242

CCN(N1CCCC1)S(=O)(=O)c1ccc(Nc2ncc(NC(=O)c3cc(O)ccc3Cl)cn2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.48
▸ LMNA P02545 4/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ GFER P55789 1/20 0.48
▸ TSHR P16473 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ SRC P12931 4/20 0.42
▸ ABL1 P00519 3/20 0.42
▸ PABPC1 P11940 1/20 0.41
▸ LCK P06239 3/20 0.41
▸ MAPK14 Q16539 3/20 0.41
▸ KDR P35968 1/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ SMO Q99835 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5997326 0.91 KMT2A (0.46) ALDH1A1LMNAKDM4EGFERTSHR
SCHEMBL5998288 0.84 LCK (0.56) LCKMAPK14KMT2ARAB9ANPC1
SCHEMBL2498339 0.84 BTK (0.61) SRCABL1LCKMAPK14KDR
SCHEMBL5996066 0.83 LCK (0.45) ALDH1A1LMNAKDM4EGFERTSHR
SCHEMBL5997079 0.80 LCK (0.44) ALDH1A1LMNATSHRSRCABL1
SCHEMBL5995458 0.79 SRC (0.56) ALDH1A1LMNAKDM4EGFERTSHR
SCHEMBL5996220 0.79 SRC (0.56) ALDH1A1LMNAKDM4EGFERTSHR
SCHEMBL2495247 0.79 BTK (0.63) SRCABL1LCKMAPK14KDR
SCHEMBL5995241 0.77 LMNA (0.56) ALDH1A1LMNAKDM4EGFERTSHR
SCHEMBL5994786 0.76 HSD11B1 (0.40) ALDH1A1KDM4ESRCABL1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060247250-A1 Pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2006-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247250-A1 Pyrimidine inhibitors of kinases DTYMK, SRC, DCK ALDH1A1 3321/4885LMNA 4816/4885KDM4E 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback